Published in Infect Immun on February 01, 1995
Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A (2005) 6.39
Antibodies against merozoite surface protein (MSP)-1(19) are a major component of the invasion-inhibitory response in individuals immune to malaria. J Exp Med (2001) 2.80
Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun (1995) 2.48
Fine specificity of serum antibodies to Plasmodium falciparum merozoite surface protein, PfMSP-1(19), predicts protection from malaria infection and high-density parasitemia. Infect Immun (2004) 2.31
Long-lived antibody and B Cell memory responses to the human malaria parasites, Plasmodium falciparum and Plasmodium vivax. PLoS Pathog (2010) 2.30
Immunoglobulin G subclass-specific responses against Plasmodium falciparum merozoite antigens are associated with control of parasitemia and protection from symptomatic illness. Infect Immun (2009) 2.22
Genetic diversity and malaria vaccine design, testing and efficacy: preventing and overcoming 'vaccine resistant malaria'. Parasite Immunol (2009) 2.17
Levels of antibody to conserved parts of Plasmodium falciparum merozoite surface protein 1 in Ghanaian children are not associated with protection from clinical malaria. Infect Immun (1999) 2.16
Target antigen, age, and duration of antigen exposure independently regulate immunoglobulin G subclass switching in malaria. Infect Immun (2006) 1.87
Dynamics of polymorphism in a malaria vaccine antigen at a vaccine-testing site in Mali. PLoS Med (2007) 1.78
Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun (1996) 1.78
Characterization of human T- and B-cell epitopes in the C terminus of Plasmodium falciparum merozoite surface protein 1: evidence for poor T-cell recognition of polypeptides with numerous disulfide bonds. Infect Immun (1997) 1.71
Associations between Burkitt lymphoma among children in Malawi and infection with HIV, EBV and malaria: results from a case-control study. PLoS One (2008) 1.70
Antibodies to the N-terminal block 2 of Plasmodium falciparum merozoite surface protein 1 are associated with protection against clinical malaria. Infect Immun (2004) 1.60
Acquired immune responses to the N- and C-terminal regions of Plasmodium vivax merozoite surface protein 1 in individuals exposed to malaria. Infect Immun (1997) 1.53
Genetic diversity and antigenic polymorphism in Plasmodium falciparum: extensive serological cross-reactivity between allelic variants of merozoite surface protein 2. Infect Immun (2003) 1.44
The fine specificity, but not the invasion inhibitory activity, of 19-kilodalton merozoite surface protein 1-specific antibodies is associated with resistance to malarial parasitemia in a cross-sectional survey in The Gambia. Infect Immun (2004) 1.44
Differential patterns of human immunoglobulin G subclass responses to distinct regions of a single protein, the merozoite surface protein 1 of Plasmodium falciparum. Infect Immun (2001) 1.44
Analysis of antibodies directed against merozoite surface protein 1 of the human malaria parasite Plasmodium falciparum. Infect Immun (2006) 1.32
Immunization of Aotus nancymai with recombinant C terminus of Plasmodium falciparum merozoite surface protein 1 in liposomes and alum adjuvant does not induce protection against a challenge infection. Infect Immun (1996) 1.29
Protective immune responses to the 42-kilodalton (kDa) region of Plasmodium yoelii merozoite surface protein 1 are induced by the C-terminal 19-kDa region but not by the adjacent 33-kDa region. Infect Immun (2002) 1.19
Relationship between maternally derived anti-Plasmodium falciparum antibodies and risk of infection and disease in infants living in an area of Liberia, west Africa, in which malaria is highly endemic. Infect Immun (1995) 1.14
The breadth, but not the magnitude, of circulating memory B cell responses to P. falciparum increases with age/exposure in an area of low transmission. PLoS One (2011) 1.14
Naturally acquired antibody responses to Plasmodium falciparum merozoite surface protein 4 in a population living in an area of endemicity in Vietnam. Infect Immun (2001) 1.11
Acquisition of antibodies against Plasmodium falciparum merozoites and malaria immunity in young children and the influence of age, force of infection, and magnitude of response. Infect Immun (2014) 1.06
Regulation of antigen-specific immunoglobulin G subclasses in response to conserved and polymorphic Plasmodium falciparum antigens in an in vitro model. Infect Immun (2002) 1.05
Protection against Plasmodium chabaudi malaria induced by immunization with apical membrane antigen 1 and merozoite surface protein 1 in the absence of gamma interferon or interleukin-4. Infect Immun (2004) 1.00
Isolation and characterization of the MSP1 genes from Plasmodium malariae and Plasmodium ovale. Am J Trop Med Hyg (2010) 0.99
Comparison of immunogenicities of recombinant Plasmodium vivax merozoite surface protein 1 19- and 42-kiloDalton fragments expressed in Escherichia coli. Infect Immun (2004) 0.98
Enhanced protection against malaria by a chimeric merozoite surface protein vaccine. Infect Immun (2006) 0.97
A Plasmodium vivax vaccine candidate displays limited allele polymorphism, which does not restrict recognition by antibodies. Mol Med (1999) 0.93
Baculovirus-based nasal drop vaccine confers complete protection against malaria by natural boosting of vaccine-induced antibodies in mice. Infect Immun (2009) 0.93
Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure. PLoS One (2014) 0.92
Antibodies elicited in adults by a primary Plasmodium falciparum blood-stage infection recognize different epitopes compared with immune individuals. Malar J (2007) 0.91
Role of cysteines in Plasmodium falciparum circumsporozoite protein: interactions with heparin can rejuvenate inactive protein mutants. Proc Natl Acad Sci U S A (2000) 0.90
Alteration in host cell tropism limits the efficacy of immunization with a surface protein of malaria merozoites. Infect Immun (2005) 0.89
Allele specificity of gamma interferon responses to the carboxyl-terminal region of Plasmodium falciparum merozoite surface protein 1 by Kenyan adults with naturally acquired immunity to malaria. Infect Immun (2010) 0.89
In vivo expression and immunological studies of the 42-kilodalton carboxyl-terminal processing fragment of Plasmodium falciparum merozoite surface protein 1 in the baculovirus-silkworm system. Infect Immun (2002) 0.88
Antibody responses to the merozoite surface protein-1 complex in cerebral malaria patients in India. Malar J (2008) 0.87
Isolation, production and characterization of fully human monoclonal antibodies directed to Plasmodium falciparum MSP10. Malar J (2015) 0.86
Integration of Multiplex Bead Assays for Parasitic Diseases into a National, Population-Based Serosurvey of Women 15-39 Years of Age in Cambodia. PLoS Negl Trop Dis (2016) 0.84
Monitoring changes in malaria epidemiology and effectiveness of interventions in Ethiopia and Uganda: Beyond Garki Project baseline survey. Malar J (2015) 0.82
Effect of transmission intensity and age on subclass antibody responses to Plasmodium falciparum pre-erythrocytic and blood-stage antigens. Acta Trop (2014) 0.78
Distinct patterns of blood-stage parasite antigens detected by plasma IgG subclasses from individuals with different level of exposure to Plasmodium falciparum infections. Malar J (2010) 0.78
Malaria epidemiology in central Myanmar: identification of a multi-species asymptomatic reservoir of infection. Malar J (2017) 0.78
The profile of IgG-antibody response against merozoite surface proteins 1 and 2 in severe Plasmodium falciparum malaria in Eastern Sudan. Parasitol Res (2007) 0.77
Plasmodium falciparum: immunization with MSP1-42 induced non-inhibitory antibodies that have no blocking activities but enhanced the potency of inhibitory anti-MSP1-42 antibodies. Exp Parasitol (2006) 0.76
Optimized Malaria-antigens delivered by immunostimulating reconstituted influenza virosomes. Wien Klin Wochenschr (2006) 0.76
Longevity of Genotype-Specific Immune Responses to Plasmodium falciparum Merozoite Surface Protein 1 in Kenyan Children from Regions of Different Malaria Transmission Intensity. Am J Trop Med Hyg (2016) 0.75
Single-step purification of polypeptides expressed in Escherichia coli as fusions with glutathione S-transferase. Gene (1988) 52.71
Mortality and morbidity from malaria among children in a rural area of The Gambia, West Africa. Trans R Soc Trop Med Hyg (1987) 6.58
A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med (1990) 4.90
Analysis of sequence diversity in the Plasmodium falciparum merozoite surface protein-1 (MSP-1). Mol Biochem Parasitol (1993) 3.99
Merozoite surface coat precursor protein completely protects Aotus monkeys against Plasmodium falciparum malaria. Proc Natl Acad Sci U S A (1987) 3.31
Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature (1985) 3.19
Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol (1992) 3.12
Immunization against malaria with a recombinant protein. Parasite Immunol (1994) 2.89
Major surface antigen gene of a human malaria parasite cloned and expressed in bacteria. Nature (1984) 2.74
Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol (1994) 2.71
A recombinant 15-kilodalton carboxyl-terminal fragment of Plasmodium yoelii yoelii 17XL merozoite surface protein 1 induces a protective immune response in mice. Infect Immun (1993) 2.57
Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol Biochem Parasitol (1987) 2.56
The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J Exp Med (1984) 2.40
Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol (1991) 2.32
A carboxyl-terminal fragment of Plasmodium falciparum gp195 expressed by a recombinant baculovirus induces antibodies that completely inhibit parasite growth. J Immunol (1992) 2.32
Surface antigens of malaria merozoites. A high molecular weight precursor is processed to an 83,000 mol wt form expressed on the surface of Plasmodium falciparum merozoites. J Exp Med (1983) 2.30
Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol (1992) 2.28
Characterization with monoclonal antibodies of a surface antigen of Plasmodium falciparum merozoites. J Immunol (1985) 2.26
Antimalarial immunity in Saimiri monkeys. Immunization with surface components of asexual blood stages. J Exp Med (1984) 2.16
Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol (1993) 2.14
The solution structure of human epidermal growth factor. Nature (1987) 1.94
Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol (1991) 1.92
Expression and antigenicity of Plasmodium falciparum major merozoite surface protein (MSP1(19)) variants secreted from Saccharomyces cerevisiae. Mol Biochem Parasitol (1994) 1.86
Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature (1987) 1.85
Mapping of the region predominantly recognized by antibodies to the Plasmodium falciparum merozoite surface antigen MSA 1. Mol Biochem Parasitol (1992) 1.64
Ability of recombinant or native proteins to protect monkeys against heterologous challenge with Plasmodium falciparum. Infect Immun (1991) 1.60
Serological cross-reaction between high molecular weight proteins synthesized in blood schizonts of Plasmodium yoelii, Plasmodium chabaudi and Plasmodium falciparum. Mol Biochem Parasitol (1983) 1.41
Immunization with synthetic peptides of a Plasmodium falciparum surface antigen induces antimerozoite antibodies. Proc Natl Acad Sci U S A (1986) 1.32
Immunization of Aotus monkeys with Plasmodium falciparum blood-stage recombinant proteins. Proc Natl Acad Sci U S A (1990) 1.28
Sequence conservation in the C-terminal part of the precursor to the major merozoite surface proteins (MSP1) of Plasmodium falciparum from field isolates. Mol Biochem Parasitol (1993) 1.26
Topography of epitopes on a polymorphic schizont antigen of Plasmodium falciparum determined by the binding of monoclonal antibodies in a two-site radioimmunoassay. Parasite Immunol (1987) 1.19
A protective monoclonal antibody recognizes a variant-specific epitope in the precursor of the major merozoite surface antigen of the rodent malarial parasite Plasmodium yoelii. J Immunol (1989) 1.17
Synthesis of merozoite proteins and glycoproteins during the schizogony of Plasmodium falciparum. Mol Biochem Parasitol (1984) 1.11
Titration of antibodies. J Immunol Methods (1992) 1.06
Human-human hybridomas secreting monoclonal antibodies to the Mr 195,000 Plasmodium falciparum blood stage antigen. J Exp Med (1986) 0.89
Characterization of an immediate-early gene induced in adherent monocytes that encodes I kappa B-like activity. Cell (1991) 6.49
Estimating medium- and long-term trends in malaria transmission by using serological markers of malaria exposure. Proc Natl Acad Sci U S A (2005) 6.39
A family of erythrocyte binding proteins of malaria parasites. Proc Natl Acad Sci U S A (1992) 5.40
A single fragment of a malaria merozoite surface protein remains on the parasite during red cell invasion and is the target of invasion-inhibiting antibodies. J Exp Med (1990) 4.90
Immunization against blood-stage rodent malaria using purified parasite antigens. Nature (1981) 4.40
Biosynthesis and processing of a Plasmodium falciparum schizont antigen recognized by immune serum and a monoclonal antibody. J Exp Med (1982) 3.88
Clinical immunity to Plasmodium falciparum malaria is associated with serum antibodies to the 19-kDa C-terminal fragment of the merozoite surface antigen, PfMSP-1. J Infect Dis (1996) 3.49
Sporadic urban leptospirosis. Ann Intern Med (1996) 3.48
Primary structure of the precursor to the three major surface antigens of Plasmodium falciparum merozoites. Nature (1985) 3.19
Plasmodium malariae infection in an asymptomatic 74-year-old Greek woman with splenomegaly. N Engl J Med (1998) 3.13
Naturally acquired cellular and humoral immune responses to the major merozoite surface antigen (PfMSP1) of Plasmodium falciparum are associated with reduced malaria morbidity. Parasite Immunol (1992) 3.12
A principal target of human immunity to malaria identified by molecular population genetic and immunological analyses. Nat Med (2000) 3.06
Dissociable neural responses to facial expressions of sadness and anger. Brain (1999) 2.94
A longitudinal study of type-specific antibody responses to Plasmodium falciparum merozoite surface protein-1 in an area of unstable malaria in Sudan. J Immunol (1998) 2.94
Antibodies inhibit the protease-mediated processing of a malaria merozoite surface protein. J Exp Med (1994) 2.94
Antibodies that inhibit malaria merozoite surface protein-1 processing and erythrocyte invasion are blocked by naturally acquired human antibodies. J Exp Med (1997) 2.92
Transdermal nicotine for active ulcerative colitis. N Engl J Med (1994) 2.90
Immunization against malaria with a recombinant protein. Parasite Immunol (1994) 2.89
Association between alpha-tocopherol, gamma-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst (2000) 2.77
Expression of the 19-kilodalton carboxy-terminal fragment of the Plasmodium falciparum merozoite surface protein-1 in Escherichia coli as a correctly folded protein. Mol Biochem Parasitol (1994) 2.71
Absolute levels and ratios of proinflammatory and anti-inflammatory cytokine production in vitro predict clinical immunity to Plasmodium falciparum malaria. J Infect Dis (2002) 2.61
Human T-cell recognition of the circumsporozoite protein of Plasmodium falciparum: immunodominant T-cell domains map to the polymorphic regions of the molecule. Proc Natl Acad Sci U S A (1988) 2.60
Fragments of the polymorphic Mr 185,000 glycoprotein from the surface of isolated Plasmodium falciparum merozoites form an antigenic complex. Mol Biochem Parasitol (1987) 2.56
Immunogenicity and in vivo efficacy of recombinant Plasmodium falciparum merozoite surface protein-1 in Aotus monkeys. Mol Med (1995) 2.48
Human antibody response to Plasmodium falciparum merozoite surface protein 2 is serogroup specific and predominantly of the immunoglobulin G3 subclass. Infect Immun (1995) 2.48
IgG3 antibodies to Plasmodium falciparum merozoite surface protein 2 (MSP2): increasing prevalence with age and association with clinical immunity to malaria. Am J Trop Med Hyg (1998) 2.41
The three major antigens on the surface of Plasmodium falciparum merozoites are derived from a single high molecular weight precursor. J Exp Med (1984) 2.40
Human antibodies to the 19kDa C-terminal fragment of Plasmodium falciparum merozoite surface protein 1 inhibit parasite growth in vitro. Parasite Immunol (1999) 2.39
The precursor to major merozoite surface antigens: structure and role in immunity. Prog Allergy (1988) 2.35
Dietary fish oil reduces O6-methylguanine DNA adduct levels in rat colon in part by increasing apoptosis during tumor initiation. Cancer Epidemiol Biomarkers Prev (2000) 2.33
A longitudinal investigation of IgG and IgM antibody responses to the merozoite surface protein-1 19-kiloDalton domain of Plasmodium falciparum in pregnant women and infants: associations with febrile illness, parasitemia, and anemia. Am J Trop Med Hyg (1998) 2.33
Proteolytic processing of the Plasmodium falciparum merozoite surface protein-1 produces a membrane-bound fragment containing two epidermal growth factor-like domains. Mol Biochem Parasitol (1991) 2.32
Surface antigens of malaria merozoites. A high molecular weight precursor is processed to an 83,000 mol wt form expressed on the surface of Plasmodium falciparum merozoites. J Exp Med (1983) 2.30
Neurological disorders and adult coeliac disease. Gut (1970) 2.29
Immunization with parasite-derived apical membrane antigen 1 or passive immunization with a specific monoclonal antibody protects BALB/c mice against lethal Plasmodium yoelii yoelii YM blood-stage infection. Infect Immun (2000) 2.29
Secondary processing of the Plasmodium falciparum merozoite surface protein-1 (MSP1) by a calcium-dependent membrane-bound serine protease: shedding of MSP133 as a noncovalently associated complex with other fragments of the MSP1. Mol Biochem Parasitol (1992) 2.28
Design of an epidemiologic study of drinking water arsenic exposure and skin and bladder cancer risk in a U.S. population. Environ Health Perspect (1998) 2.22
Maintaining the immunological balance in parasitic infections: a role for TGF-beta? Parasitol Today (2000) 2.19
The war between the malaria parasite and the immune system: immunity, immunoregulation and immunopathology. Clin Exp Immunol (2003) 2.18
Toenail trace element levels as biomarkers: reproducibility over a 6-year period. Cancer Epidemiol Biomarkers Prev (1993) 2.15
Prospective study of serum micronutrients and ovarian cancer. J Natl Cancer Inst (1996) 2.15
Polymorphism of a high molecular weight schizont antigen of the human malaria parasite Plasmodium falciparum. J Exp Med (1985) 2.15
Recombinant Pfs25 protein of Plasmodium falciparum elicits malaria transmission-blocking immunity in experimental animals. J Exp Med (1991) 2.15
Monoclonal antibodies that inhibit Plasmodium falciparum invasion in vitro recognise the first growth factor-like domain of merozoite surface protein-1. Mol Biochem Parasitol (1993) 2.14
Antigenic diversity in the human malaria parasite Plasmodium falciparum. Science (1982) 2.09
Cloning of the Plasmodium vivax Duffy receptor. Mol Biochem Parasitol (1991) 2.05
Stroke in a cohort of patients with homozygous sickle cell disease. J Pediatr (1992) 2.02
Glycopeptides from variant surface glycoproteins of Trypanosoma Brucei. C-terminal location of antigenically cross-reacting carbohydrate moieties. Mol Biochem Parasitol (1981) 2.00
Selenium, retinol, retinol-binding protein, and uric acid. Associations with cancer mortality in a population-based prospective case-control study. Ann Epidemiol (1991) 1.98
Processing of the precursor to the major merozoite surface antigens of Plasmodium falciparum. Parasitology (1987) 1.93
Processing of the Plasmodium falciparum major merozoite surface protein-1: identification of a 33-kilodalton secondary processing product which is shed prior to erythrocyte invasion. Mol Biochem Parasitol (1991) 1.92
A malaria merozoite surface protein (MSP1)-structure, processing and function. Mem Inst Oswaldo Cruz (1992) 1.91
CpG island methylation in colorectal adenomas. Am J Pathol (2001) 1.88
Inhibitory and blocking monoclonal antibody epitopes on merozoite surface protein 1 of the malaria parasite Plasmodium falciparum. J Mol Biol (2001) 1.87
Prospective study of toenail selenium levels and cancer among women. J Natl Cancer Inst (1995) 1.85
Shotgun DNA microarrays and stage-specific gene expression in Plasmodium falciparum malaria. Mol Microbiol (2000) 1.84
Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial. Infect Immun (2001) 1.81
Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum. Mol Biochem Parasitol (1996) 1.80
Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am J Epidemiol (2001) 1.80
Identification of T and B cell epitopes recognized by humans in the C-terminal 42-kDa domain of the Plasmodium falciparum merozoite surface protein (MSP)-1. J Immunol (1995) 1.79
Comparison of homozygous sickle cell disease in northern Greece and Jamaica. Lancet (1990) 1.78
Natural immune response to the C-terminal 19-kilodalton domain of Plasmodium falciparum merozoite surface protein 1. Infect Immun (1996) 1.78
High-resolution serum proteomic patterns for ovarian cancer detection. Endocr Relat Cancer (2004) 1.76
Pathways and strategies for developing a malaria blood-stage vaccine. Annu Rev Immunol (1998) 1.75
Pgs28 belongs to a family of epidermal growth factor-like antigens that are targets of malaria transmission-blocking antibodies. J Exp Med (1993) 1.73
Isoniazid preventive therapy for tuberculosis in HIV-1-infected adults: results of a randomized controlled trial. AIDS (1997) 1.73
Immunogenicity and efficacy in aotus monkeys of four recombinant Plasmodium falciparum vaccines in multiple adjuvant formulations based on the 19-kilodalton C terminus of merozoite surface protein 1. Infect Immun (2000) 1.71
Diagnositic value of serum bile acid estimations in liver disease. J Clin Pathol (1975) 1.71
A novel malaria protein, Pfs28, and Pfs25 are genetically linked and synergistic as falciparum malaria transmission-blocking vaccines. Infect Immun (1997) 1.71
Crossmodal binding of fear in voice and face. Proc Natl Acad Sci U S A (2001) 1.71
Coeliac infertility: an indication for dietary gluten restriction? Lancet (1970) 1.69
Measurement of low levels of arsenic exposure: a comparison of water and toenail concentrations. Am J Epidemiol (2000) 1.69
Characteristics of the protective response of BALB/c mice immunized with a purified Plasmodium yoelii schizont antigen. Clin Exp Immunol (1983) 1.69
Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum. Mol Cell Biol (1991) 1.68
Transmission-blocking activity of a chitinase inhibitor and activation of malarial parasite chitinase by mosquito protease. Proc Natl Acad Sci U S A (1993) 1.68
Analysis of human antibodies to erythrocyte binding antigen 175 of Plasmodium falciparum. Infect Immun (2000) 1.66
Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria. J Infect Dis (1998) 1.66
Neural activity associated with episodic memory for emotional context. Neuropsychologia (2001) 1.65
A rapid biochemical method for purifying lambda DNA from phage lysates. Nucleic Acids Res (1986) 1.62
Solution structure of an EGF module pair from the Plasmodium falciparum merozoite surface protein 1. J Mol Biol (1999) 1.61
Behçet's syndrome: severe proctitis with rectovaginal fistula formation. Ann Rheum Dis (1989) 1.61
Genetic regulation of protective immune response in congenic strains of mice vaccinated with a subunit malaria vaccine. J Immunol (1996) 1.60
Adhesion-dependent regulation of an A+U-rich element-binding activity associated with AUF1. Mol Cell Biol (1997) 1.59
Arsenic and noncirrhotic portal hypertension. Gastroenterology (1974) 1.57
Transforming growth factor beta production is inversely correlated with severity of murine malaria infection. J Exp Med (1998) 1.57
Immunization with a recombinant C-terminal fragment of Plasmodium yoelii merozoite surface protein 1 protects mice against homologous but not heterologous P. yoelii sporozoite challenge. Infect Immun (1997) 1.57
The epidemiology of multiple-clone Plasmodium falciparum infections in Gambian patients. Parasitology (1991) 1.55
A longitudinal study of naturally acquired cellular and humoral immune responses to a merozoite surface protein (MSP1) of Plasmodium falciparum in an area of seasonal malaria transmission. Parasite Immunol (1993) 1.54
Prediagnostic serum selenium and risk of cancer. Lancet (1983) 1.54